Virbac Welcomes Paul Martingell as New CEO Set for 2025
Introducing Paul Martingell: Virbac's New Chief Executive Officer
Virbac is excited to announce that Paul Martingell has been appointed as the chief executive officer, effective September 1, 2025. His extensive background in international consumer health sectors makes him an exceptional fit for this pivotal role.
Leadership Background and Experience
At the age of 45, Paul Martingell has already made a significant impact in the field, noted for his capability to inspire diverse teams and navigate complexities. He holds an MBA with distinction in Mergers and Acquisitions and is a recognized Chartered Accountant in the UK. With over 25 years of substantial international experience, he has built a significant career in consumer health, pharmaceuticals, and consumer goods.
Martingell's professional journey includes influential roles throughout Europe, Asia, and Latin America. He began his career at Ernst & Young (EY), moving on to Reckitt Benckiser and Novartis Consumer Healthcare. Most recently, he was part of the executive committee overseeing the merger of Boehringer Ingelheim and Sanofi's Consumer Healthcare businesses, where he played a leading role developing essential markets.
Vision and Commitment to Animal Health
Martingell’s leadership style emphasizes fostering collaborative and agile teams. He has a proven track record of creating vision-driven strategies and executing transformative initiatives to achieve outstanding results. In a statement expressing his enthusiasm, Paul said, "Joining Virbac offers an exciting opportunity to delve into the world of animal health. I am eager to collaborate with Virbac's exceptional teams to innovate and build on our strong foundations for a positive impact on animals, their owners, and veterinarians globally."
Board's Confidence in New CEO
Marie-Hélène Dick, chairwoman of Virbac's board of directors, expressed confidence in Martingell's capabilities, saying that his impressive background, energy, and human-focused approach make him ideal for guiding the company. With his comprehensive understanding of the consumer health sector and his ability to embrace new challenges, the board believes he will contribute significantly to the Group's ongoing evolution.
Expressions of Gratitude
The board also took a moment to thank Habib Ramdani for his dedication and professionalism while serving as interim chief executive officer, laying a solid groundwork for the transition.
About Virbac: Supporting Animal Health
Virbac is dedicated to advancing the health of animals through continuous innovation in the prevention, diagnosis, and treatment of various animal pathologies. Their product offerings, including care, hygiene, and nutrition products, are designed to support veterinarians, farmers, and pet owners worldwide. Virbac believes in partnering with those who care for animals daily, fostering a shared mission of improving lives together.
Contact Information
For more information, please contact Virbac via the following:
Julie Adam - j.adam-externe@libremullenlowe.fr - +33 7 86 82 60 61
Melina Constantinidis - c.constantinidis@libremullenlowe.fr - +33 7 63 18 97 34
Frequently Asked Questions
When will Paul Martingell officially start as CEO?
Paul Martingell will begin his role as CEO on September 1, 2025.
What is Paul Martingell's professional background?
He has over 25 years of experience in consumer health, pharmaceuticals, and consumer goods, with significant roles at Ernst & Young, Reckitt Benckiser, and Novartis.
What qualities does Paul bring to Virbac?
He is noted for his ability to inspire international teams, lead transformations, and build collaborative visions in organizations.
What does Virbac focus on as a company?
Virbac is dedicated to developing products for preventing, diagnosing, and treating animal health issues while supporting veterinarians, farmers, and pet owners.
Who preceded Paul Martingell as CEO?
Habib Ramdani served as the interim CEO before Paul Martingell's appointment.
About The Author
Contact Henry Turner privately here. Or send an email with ATTN: Henry Turner as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.
